| 货号 | HF943086 |
|---|
| 品牌 | abinScience |
|---|
| 种属反应性 | Human |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 宿主 | Human |
|---|
| 同种型 | IgG |
|---|
| 克隆号 | SK48-E26 |
|---|
| 生物活性 | SK48-E26 effectively captures human recombinant IL-1β in an ELISA format, enabling detection of hrIL-1β at concentrations as low as 0.1 to 0.2 ng/mL with a linear response to IL-1β concentration [1]. SK48-E26 specifically neutralizes human recombinant IL-1β activity in an EL-4 cell-based bioassay, binds a conformational epitope on hrIL-1β spanning amino acids 95-101, and has an affinity for IL-1β of 0.5 to 3 nM [1]. Mutations in the heavy chain CDR3 region of SK48-E26 Fab fragments increase affinity for human recombinant IL-1β, with the V120T/R121K mutant showing a 9.79-fold improvement over the wild-type SK48-E26 Fab [1]. SK48-E26 (10-200 nM) binds to human IL-1β with an equilibrium dissociation constant of 242 pM [2]. SK48-E26 (1×10 -15 -1×10 -7 M; 1 h pre-incubation with IL-1β, 16-20 h incubation with cells) neutralizes human IL-1β with an IC 50 of 400 pM and cynomolgus IL-1β with an IC 50 of 185 pM in MRC-5 cells [2]. |
|---|
| 表达系统 | Mammalian cells |
|---|
| 克隆类型 | Monoclonal |
|---|
| 靶标 | Interleukin-1 beta, IL1B, Catabolin, IL1F2, IL-1 beta |
|---|
| 内毒素水平 | < 10 EU/mg |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| Accession号 | P01584 |
|---|
| 状态 | Liquid |
|---|
| 保存溶液 |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
|---|
| 别名 | SK48-E26, SK48E26, SK48E26 |
|---|
| 背景 | Interleukin-1 beta (IL1B/IL1F2) is a ~30 kDa protein. Potent pro-inflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells. Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6. IL1B is the therapeutic target of canakinumab (Ilaris). 1. Tominaga, K. et al. (2000) International immunology 12, 151-60. PMID: 106538502. Nakahara, H. et al. (2003) Arthritis and rheumatism 48, 1521-9. PMID: 127948195. Tian, XX. et al. (2021) International endodontic journal 54, 916-925. PMID: 33377178 |
|---|
| 文献 | 1. Peter Ronald Young, et al. RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN. WO1995001997A1. 1994. [HF943086]
2. Lacy SE, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. MAbs. 2015;7(3):605-19. [HF943086] |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
